AZN vs EMBC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.
EMBC shows neutral fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AZN vs EMBC: Head-to-Head Comparison
This page compares AstraZeneca PLC (AZN) and Embecta Corp. (EMBC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.